Cambridge, UK: Domainex Ltd, specialists in drug discovery solutions and translational research support, has today announced that it is launching its Discovery STAR Award to support academic groups at the early stages of drug discovery.
5th November 2012
Domainex Ltd has developed a number of chemical series with potent and selective activity against two closely related kinases TBK1 and IKK- epsilon.
6th August 2012
Domainex and Horizon announce collaboration in support of Domainex's TBK1/IKKe Inhibitor Program.
2nd August 2012
Domainex successful in securing Biomedical Catalyst Feasibility Award
12th March 2012
Combinatorial domain hunting technology aids identification of MEK protein suitable for structure-based drug discovery New structural information allowed UCB scientists to design a novel class of molecules which inhibit MEK
6th January 2012
Download Press release
29th November 2011
Domainex to Present at a Range of Industry Events in December 2011, including Epigenetics Summit in Munich, including:
8th November 2011
This is to recognise its work on the development of a new cancer drug against the novel kinase targets TBK1/IKKe.
1st November 2011
Domainex has been awarded a £250,000 grant by the Technology Strategy Board to support development of a new drug for treatment of several common cancers.
1st October 2011
Chemical & Engineering News (External link)